Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
22:06
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

International Liver Cancer Association 14th Annual Conference

 

September 11-13, 2020 Virtual Conference
FAQs
   
Discussion forum - International Liver Cancer Association 20th Annual Conference
    Topic - Clinical Trials in progress

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Phase 3 Keynote-937: Adjuvant Pembrolizumab Versus Placebo In Patients With Hepatocellular Carcinoma And Complete Radiologic Response After Surgical Resection Or Local Ablation  Neehar Parikh 1      9/22/2020 1:28:00 PM  
Ramucirumab For Patients With Advanced Hepatocellular Carcinoma And Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results From An Expansion Cohort Of The Phase 3 Reach-2 Study  Cristina Miralles 1      9/22/2020 1:28:00 PM  
Leap-012: A Randomized, Double-Blind, Phase 3 Study Of Pembrolizumab Plus Lenvatinib In Combination With Transarterial Chemoembolization (Tace) In Patients With Intermediate-Stage Hepatocellular Carcinoma (Hcc) Not Amenable To Curative Treatment  Neehar Parikh 1      9/22/2020 1:28:00 PM  
Pembrolizumab In Combination With Gemcitabine And Cisplatin For The Treatment Of Advanced Biliary Tract Cancer: Phase 3 Keynote-966 Trial In Progress  Neehar Parikh 1      9/22/2020 1:28:00 PM  
Durvalumab With Or Without Bevacizumab As Adjuvant Therapy For HCC Patients At Risk Of Recurrence After Curative Therapy: EMERALD-2  Jingyu Hou 1      9/22/2020 1:28:00 PM  
Hcc Recurrence Post Daa And Its Relation To Treatment Time Of Chronic Hcv Infection  Mohamed Fathey Abdelkhalek Elgazzar 1      9/22/2020 1:28:00 PM  
Sorafenib (Sor) Combined With Nivolumab (Nivo) In Advanced Hepatocellular Carcinoma (Hcc): Safety And Efficacy In A Dose Escalation Cohort  Bridget Keenan 1      9/22/2020 1:28:00 PM  
A Randomized, Placebo-Controlled Study Of Transarterial Chemoembolization Combined With Concurrent Durvalumab Followed By Durvalumab Or Durvalumab Plus Bevacizumab Therapy In Patients With Locoregional Hepatocellular Carcinoma (HCC): EMERALD-1  Bruno Sangro 1      9/22/2020 1:28:00 PM  
       




Most viewed poster for this congress
Poster: 1
Visits: 241
Title: Pembrolizumab In Combination With Gemcitabine And Cisplatin For The Treatment Of Advanced Biliary Tract Cancer: Phase 3 Keynote-966 Trial In Progress
Authors: Robin Kelley , R.K. KELLEY, A. VOGEL, R.S. FINN, J. FURUSE, J. EDELINE, Z. REN, S.-C. SU, U. MALHOTRA, A.B. SIEGEL, J.W. VALLE
Centre: 

Poster most viewed in this topic
Poster: 3
Visits: 186
Title: Ramucirumab For Patients With Advanced Hepatocellular Carcinoma And Elevated Alpha Fetoprotein Following A Non-Sorafenib Based Systemic Therapy: Interim Results From An Expansion Cohort Of The Phase 3 Reach-2 Study
Authors: David Mcilwain ,
Centre: 


 




PosterSessionOnline
Logo Draft
 
Logo Cert